IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of "Moderate Buy" From Analysts
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of "Moderate Buy" From Analysts
IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Rating) has earned an average recommendation of "Moderate Buy" from the six brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $27.50.
据MarketBeat报道,IDEAYA生物科学公司(纳斯达克代码:IDYA-GET Rating)已经获得了报道该公司的六家券商的平均推荐“适度买入”。一位股票研究分析师对该股的评级为持有建议,三位分析师给该公司指定了买入建议。在过去一年发布该股报告的分析师中,12个月目标价平均为27.50美元。
Several equities analysts have recently issued reports on the stock. Robert W. Baird lowered their target price on shares of IDEAYA Biosciences from $26.00 to $18.00 and set an "outperform" rating for the company in a report on Tuesday, August 16th. Stifel Nicolaus lowered shares of IDEAYA Biosciences from a "buy" rating to a "hold" rating and lowered their target price for the company from $16.00 to $13.00 in a report on Monday, August 15th. Oppenheimer lifted their target price on shares of IDEAYA Biosciences to $22.00 in a report on Tuesday, September 6th. Finally, Guggenheim boosted their price objective on shares of IDEAYA Biosciences from $20.00 to $32.00 and gave the stock a "buy" rating in a report on Tuesday, September 13th.
几位股票分析师最近发布了关于该股的报告。罗伯特·W·贝尔德在8月16日周二的一份报告中将IDEAYA生物科学公司的股票目标价从26.00美元下调至18.00美元,并为该公司设定了“跑赢大盘”的评级。Stifel Nicolaus在8月15日周一的一份报告中将IDEAYA Biosciences的股票评级从买入下调至持有,并将该公司的目标价从16.00美元下调至13.00美元。在9月6日星期二的一份报告中,奥本海默将IDEAYA生物科学公司的股票目标价上调至22.00美元。最后,古根海姆在9月13日(星期二)的一份报告中将IDEAYA生物科学公司的股票目标价从20.00美元上调至32.00美元,并给予该股“买入”评级。
IDEAYA Biosciences Stock Performance
IDEAYA生物科学公司股票表现
IDEAYA Biosciences stock opened at $11.92 on Tuesday. The stock's 50 day simple moving average is $12.76 and its two-hundred day simple moving average is $11.99. The stock has a market cap of $468.53 million, a price-to-earnings ratio of -6.98 and a beta of 1.51. IDEAYA Biosciences has a fifty-two week low of $8.14 and a fifty-two week high of $27.69.
IDEAYA生物科学公司的股票周二开盘报11.92美元。该股的50日简单移动均线切入位为12.76美元,200日简单移动均线切入位为11.99美元。该股市值为4.6853亿美元,市盈率为-6.98倍,贝塔系数为1.51。IDEAYA Biosciences的股价为8.14美元,为52周低点,52周高点为27.69美元。
Institutional Investors Weigh In On IDEAYA Biosciences
机构投资者参与IDEAYA生物科学
A number of hedge funds have recently added to or reduced their stakes in IDYA. Victory Capital Management Inc. purchased a new stake in IDEAYA Biosciences during the 4th quarter valued at $398,000. Northern Trust Corp raised its stake in IDEAYA Biosciences by 1.2% during the 4th quarter. Northern Trust Corp now owns 312,425 shares of the company's stock valued at $7,386,000 after buying an additional 3,681 shares during the last quarter. Swiss National Bank purchased a new stake in IDEAYA Biosciences during the 4th quarter valued at $1,399,000. Bank of America Corp DE grew its position in shares of IDEAYA Biosciences by 2,298.9% during the 4th quarter. Bank of America Corp DE now owns 110,563 shares of the company's stock valued at $2,614,000 after acquiring an additional 105,954 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of IDEAYA Biosciences by 196.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 272,161 shares of the company's stock valued at $6,434,000 after acquiring an additional 180,471 shares during the period. 93.25% of the stock is currently owned by hedge funds and other institutional investors.
一些对冲基金最近增持或减持了IDYA的股份。胜利资本管理公司在第四季度购买了IDEAYA生物科学公司的新股份,价值39.8万美元。北方信托公司在第四季度将其在IDEAYA Biosciences的持股增加了1.2%。Northern Trust Corp目前持有312,425股该公司股票,价值7,386,000美元,此前该公司在上一季度又购买了3,681股。瑞士国家银行在第四季度购买了IDEAYA生物科学公司的新股份,价值1,399,000美元。美国银行DE在第四季度将其在IDEAYA生物科学公司的股票头寸增加了2,298.9%。美国银行DE目前持有110,563股该公司股票,价值2,614,000美元,在此期间又购买了105,954股。最后,Dimension Fund Advisors LP在第四季度将其在IDEAYA生物科学公司的股票头寸增加了196.8%。Dimension Fund Advisors LP在此期间额外收购了180,471股,现在拥有272,161股该公司的股票,价值6,434,000美元。93.25%的股票目前由对冲基金和其他机构投资者持有。
IDEAYA Biosciences Company Profile
IDEAYA生物科学公司简介
(Get Rating)
(获取评级)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
IDEAYA生物科学公司是一家专注于合成致命性的精确医学肿瘤学公司,专注于为使用分子诊断技术选择的患者群体发现和开发靶向疗法。该公司的主要候选产品包括甲硫氨酸腺苷转移酶2a抑制剂IDE397和蛋白激酶C抑制剂IDE196。IDE397是一种蛋氨酸腺苷转移酶2a抑制剂,正处于甲硫腺苷磷酸化酶缺失的实体肿瘤患者的第一阶段临床试验中;IDE196是一种蛋白激酶C抑制剂,正处于针对具有GNAQ或GNA11基因突变的基因定义癌症的第一/第二阶段临床试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免费获取StockNews.com关于IDEAYA生物科学的研究报告(IDYA)
- 甲骨文的短期痛苦可能是你的长期收益
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
- 自动区重新进入拉力赛模式,新高在望
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
获得IDEAYA生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对IDEAYA生物科学和相关公司的最新新闻和分析师评级的每日简要摘要。